Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy

JCO Precis Oncol. 2022 Jan:6:e2100344. doi: 10.1200/PO.21.00344.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / genetics
  • Class I Phosphatidylinositol 3-Kinases / genetics
  • Drug Combinations
  • Humans
  • MAP Kinase Kinase 1 / genetics
  • Male
  • Metformin / therapeutic use*
  • Mutation
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • Pyridones
  • Pyrimidinones
  • trametinib
  • Metformin
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human